Context Therapeutics Inc. (CNTX)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CNTX Insider Trading Activity
CNTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Insider Activity of Context Therapeutics Inc.
Over the last 12 months, insiders at Context Therapeutics Inc. have bought $0 and sold $0 worth of Context Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Context Therapeutics Inc. have bought $122,651 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,823 shares for transaction amount of $4,900 was made by Lehr Martin A. (Chief Executive Officer) on 2023‑02‑21.
List of Insider Buy and Sell Transactions, Context Therapeutics Inc.
| 2023-02-21 | Lehr Martin A. | Chief Executive Officer | 5,823 0.0382% | $0.84 | $4,900 | +28.27% | ||
| 2023-02-13 | Lehr Martin A. | Chief Executive Officer | 5,606 0.0365% | $0.87 | $4,901 | +22.21% | ||
| 2023-02-06 | Lehr Martin A. | Chief Executive Officer | 5,040 0.032% | $0.97 | $4,900 | +6.25% | ||
| 2023-01-30 | Lehr Martin A. | Chief Executive Officer | 7,027 0.0449% | $0.70 | $4,901 | +47.88% | ||
| 2023-01-23 | Lehr Martin A. | Chief Executive Officer | 6,839 0.0434% | $0.72 | $4,901 | +42.86% | ||
| 2023-01-17 | Lehr Martin A. | Chief Executive Officer | 6,783 0.0442% | $0.74 | $4,995 | +42.66% | ||
| 2022-12-16 | Lehr Martin A. | Chief Executive Officer | 20,000 0.1253% | $0.74 | $14,796 | +26.06% | ||
| 2022-12-16 | Minai-Azary Jennifer Lynn | Chief Financial Officer | 25,000 0.1566% | $0.74 | $18,500 | +26.06% | ||
| 2022-12-09 | Levit Alex C. | Chief Legal Officer, Corp. Sec | 6,000 0.0384% | $0.85 | $5,095 | +11.23% | ||
| 2022-08-19 | Lehr Martin A. | Chief Executive Officer | 13,000 0.0824% | $1.85 | $24,064 | -42.90% | ||
| 2022-08-17 | Minai-Azary Jennifer Lynn | Chief Financial Officer | 15,000 0.0939% | $1.80 | $27,000 | -41.67% | ||
| 2022-08-16 | Sahmoud Tarek | Chief Medical Officer | 10,000 0.0636% | $1.95 | $19,500 | -45.05% | ||
| 2021-12-16 | Lehr Martin A. | Chief Executive Officer | 13,000 0.4558% | $3.22 | $41,850 | -41.36% | ||
| 2021-10-22 | Lehr Martin A. | Chief Executive Officer | 10,000 0.2524% | $5.00 | $50,000 | -71.82% | ||
| 2021-10-22 | Levit Alex C. | Chief Legal Officer, Corp. Sec | 3,000 0.0757% | $5.00 | $15,000 | -71.82% |
Insider Historical Profitability
| Lehr Martin A. | Chief Executive Officer | 159701 0.2129% | $123,257.23 | 10 | 0 | +6.01% |
| Minai-Azary Jennifer Lynn | Chief Financial Officer | 40000 0.0533% | $30,872.00 | 2 | 0 | <0.0001% |
| Sahmoud Tarek | Chief Medical Officer | 10000 0.0133% | $7,718.00 | 1 | 0 | <0.0001% |
| Levit Alex C. | Chief Legal Officer, Corp. Sec | 9000 0.012% | $6,946.20 | 2 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$542,300 | 40 | -14.44% | $59.45M | |
$6,787,959 | 35 | 49.84% | $62.37M | |
$459,011,221 | 33 | 33.04% | $53.02M | |
$144,247,213 | 29 | 10.15% | $62.58M | |
$2,239,226 | 28 | 3.41% | $60.72M | |
$18,667,427 | 28 | -27.55% | $55.89M | |
$26,736,140 | 20 | -18.64% | $61.09M | |
$47,863,113 | 17 | -22.07% | $52.53M | |
$20,234,041 | 17 | 2.08% | $54.03M | |
Context Therapeutics Inc. (CNTX) | $245,302 | 15 | -4.08% | $57.88M |
$73,968,137 | 12 | -34.52% | $63.23M | |
$32,684,649 | 8 | -15.84% | $63.35M | |
$43,326,461 | 6 | 16.01% | $57.87M | |
$15,652,720 | 6 | -4.77% | $53.41M | |
$119,593,679 | 6 | -21.91% | $57.29M | |
$17,872,846 | 6 | -27.97% | $55.15M | |
$20,729,984 | 5 | 51.71% | $63.24M | |
$79,414 | 4 | 19.20% | $62.07M | |
$29,875 | 1 | -22.06% | $53.37M |
CNTX Institutional Investors: Active Positions
| Increased Positions | 28 | +62.22% | 21M | +36.64% |
| Decreased Positions | 16 | -35.56% | 5M | -8.23% |
| New Positions | 14 | New | 16M | New |
| Sold Out Positions | 4 | Sold Out | 102,879 | Sold Out |
| Total Postitions | 57 | +26.67% | 73M | +28.41% |
CNTX Ownership Change vs Market
Institutional Investor Ownership
| Mpm Bioimpact Llc | $10,382.00 | 19.61% | 14.71M | +15M | New | 2024-12-31 |
| Avidity Partners Management Lp | $5,279.00 | 9.97% | 7.48M | +60,045 | +0.81% | 2024-12-31 |
| Nextech Invest Ltd. | $5,238.00 | 9.89% | 7.42M | 0 | 0% | 2024-12-31 |
| Deep Track Capital, Lp | $5,238.00 | 9.89% | 7.42M | 0 | 0% | 2024-12-31 |
| Blue Owl Capital Holdings Lp | $4,489.00 | 8.48% | 6.36M | +946,638 | +17.49% | 2024-12-31 |
| Great Point Partners I Lp | $3,307.00 | 6.25% | 4.68M | -2M | -32.46% | 2024-12-31 |
| Franklin Resources Inc | $2,826.00 | 5.34% | 4M | +2M | +115.93% | 2024-12-31 |
| Vanguard Group Inc | $2,298.00 | 4.34% | 3.26M | -489,498 | -13.07% | 2024-12-31 |
| Blackstone Inc. | $1,723.00 | 3.25% | 2.44M | 0 | 0% | 2024-12-31 |
| Nantahala Capital Management, Llc | $1,366.00 | 2.58% | 1.94M | 0 | 0% | 2024-12-31 |